# Postural Orthostatic Tachycardia Syndrome Presenting With Recurrent Syncope After Cervical Spinal Cord Injury

**Authors:** Yonghong Liu, Boyan Fang, Qiaoxia Zhen

PMC · DOI: 10.1002/ccr3.72181 · Clinical Case Reports · 2026-02-28

## TL;DR

A man with a C2 spinal cord injury developed syncope due to postural orthostatic tachycardia syndrome, highlighting autonomic dysfunction risks.

## Contribution

This case report highlights POTS as a rare but significant cause of syncope after high cervical spinal cord injury.

## Key findings

- POTS can manifest as syncope in patients with C2 spinal cord injury.
- Heart rate variability and sympathetic skin response assessments aid in diagnosing autonomic dysfunction.
- Comprehensive rehabilitation management can resolve syncopal episodes effectively.

## Abstract

Syncope is a manifestation of autonomic dysfunction after high spinal cord injury. However, it is rarely reported as a feature of postural orthostatic tachycardia syndrome (POTS) after spinal cord injury. This case report describes a male in his 50s suffering from C2 spinal cord injury who developed recurrent postural syncope post‐injury. These events were characterized by orthostatic tachycardia upon standing and could even be induced by seated head‐tilt maneuvers, fulfilling the diagnostic criteria for POTS. These patients have substantial risks of fall‐related morbidity. Heart rate variability and sympathetic skin response assessments help elucidate the underlying autonomic pathophysiological mechanisms. Syncope may be the predominant symptom during transfers, standing, or seated head‐tilt positioning. Notably, documenting heart rate fluctuations during transient syncopal events is challenging. Infections constitute established triggers for syncope. Comprehensive management strategies may achieve complete resolution of syncopal episodes.

Postural orthostatic tachycardia syndrome can occur after high cervical spinal cord injury, even in patients with an American Spinal Injury Association Impairment Scale grade of D. Recurrent syncope during rehabilitation may be the predominant manifestation, and both heart rate variability and sympathetic skin response may facilitate and support identification of autonomic dysfunction. Comprehensive rehabilitation management demonstrates favorable therapeutic outcomes.

## Linked entities

- **Diseases:** Postural orthostatic tachycardia syndrome (MONDO:0011479), spinal cord injury (MONDO:0043797)

## Full-text entities

- **Genes:** NPPB (natriuretic peptide B) [NCBI Gene 4879] {aka BNP, Iso-ANP}, REN (renin) [NCBI Gene 5972] {aka ADTKD4, HNFJ2, RTD}, CXCR6 (C-X-C motif chemokine receptor 6) [NCBI Gene 10663] {aka BONZO, CD186, CDw186, STRL33, TYMSTR}, SLC6A2 (solute carrier family 6 member 2) [NCBI Gene 6530] {aka NAT1, NET, NET1, SLC6A5}
- **Diseases:** Inflammatory (MESH:D007249), muscle atrophy (MESH:D009133), headache (MESH:D006261), Injury (MESH:D014947), anemia (MESH:D000740), Pulmonary infection (MESH:D012141), Syncope (MESH:D013575), Orthostatic Tachycardia Syndrome (MESH:D054972), small-fiber neuropathy (MESH:D000071075), epilepsy (MESH:D004827), nutritional deficiencies (MESH:D044342), visual disturbances (MESH:D014786), AIS (MESH:C538175), peripheral autonomic injury (MESH:D059348), pain (MESH:D010146), BP drop (MESH:D006973), tonic-clonic movements (MESH:D004830), urinary or bowel retention (MESH:D016055), tremor (MESH:D014202), dyspnea (MESH:D004417), cardiovascular (MESH:D002318), Infections (MESH:D007239), Impairment (MESH:D060825), OH (MESH:D007024), weakness (MESH:D018908), UTI (MESH:D014552), spinal canal stenosis (MESH:D013130), neck stiffness (MESH:D006258), numbness (MESH:D006987), cerebrovascular disease (MESH:D002561), Anxiety (MESH:D001007), chest discomfort (MESH:D013898), dizziness (MESH:D004244), hypovolemia (MESH:D020896), PPS (MESH:D020821), IST (MESH:D013616), tachycardia (MESH:D013610), disc degeneration (MESH:D055959), Depression (MESH:D003866), torso elevation (MESH:D006937), nausea (MESH:D009325), Spinal Injury (MESH:D013124), neuropathic (MESH:D009437), tetraparesis (MESH:C565722), chest pain (MESH:D002637), fatigue (MESH:D005221), paralysis (MESH:D010243), appetite suppression (MESH:D001068), HRV (MESH:D006331), sensory loss (MESH:C580162), VVS (MESH:D019462), disorders of autonomic cardiovascular regulation (MESH:D018376), cord compression (MESH:D013117), dysregulation (MESH:D021081), BP reduction (MESH:D007022), sympathetic hyperactivity (MESH:D006948), autonomic instability (MESH:D043171), fever (MESH:D005334), HSCI (MESH:D013119), cholinergic fiber (MESH:C535672)
- **Chemicals:** salt (MESH:D012492), sodium (MESH:D012964), Duloxetine (MESH:D000068736), aldosterone (MESH:D000450), Midodrine (MESH:D008879), ivabradine (MESH:D000077550), fludrocortisone (MESH:D005438), mosapride (MESH:C062720), Metoprolol (MESH:D008790), norepinephrine (MESH:D009638)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12949424/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12949424/full.md

## References

21 references — full list in the complete paper: https://tomesphere.com/paper/PMC12949424/full.md

---
Source: https://tomesphere.com/paper/PMC12949424